Changes in trabecular microarchitecture in postmenopausal women on bisphosphonate therapy

Bone

Volumn 46, Issue 4, 2010, Pages 1006-1010

  Greenspan, Susan L ^a   Perera, Subashan ^a   Recker, Robert ^b   Wagner, Julie M ^a   Greeley, Parmatma ^a   Gomberg, Bryon R ^c   Seaman, Pamela ^c   Kleerekoper, Michael ^c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b CREIGHTON UNIVERSITY   (United States)

^c MicroMRI Inc   (United States)

Author keywords

Bisphosphonate therapy; High resolution MRI; Osteoporosis; Trabecular microarchitecture

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE EROSION; BONE STRENGTH; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HIP; HUMAN; LUMBAR SPINE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; TRABECULAR BONE; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; OSTEOPOROSIS; PATIENT SELECTION; PILOT PROJECTS; POSTMENOPAUSE;

EID: 77950532416     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.12.025     Document Type: Article

References (23)

1. Bone health and osteoporosis: a report of the surgeon general 2004, U.S. Department of Health and Human Services, U.S. Department of Health and Human Services, Office of the Surgeon General, Rockville, MD.
2. National osteoporosis foundation. clinicians guide to prevention and treatment of osteoporsis 2008, National Osteoporosis Foundation, Copyright NOF, Washington, DC.
3. Bouxsein M.L. Mechanisms of osteoporosis therapy: a bone strength perspective. Clin. Cornerstone 2003, 2:13-21.
4. Hochberg M.C., Greenspan S., Wasnich R.D., Miller P., Thompson D.E., Ross P.D. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J. Clin. Endocrinol. Metab. 2002, 87:1586-1592.
5. Cummings S.R., Karpf D.B., Harris F., Genant H.K., Ensrud K., LaCroix A.Z., et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am. J. Med. 2002, 112:281-289.
6. Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002, 359:1841-1850.
7. Borah B., Dufresne E., Chmielewski P.A., Johnson T.D., Chines A., Manhart M.D. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 2004, 34:736-746.
8. Wehrli F.W., Saha P.K., Gomberg B.R., Song H.K., Snyder P.J., Benito M., et al. Role of magnetic resonance for assessing structure and function of trabecular bone. Top Magn. Reson. Imaging 2002, 13(5):335-356.
9. Wehrli F.W., Gomberg B.R., Saha P.K., Song H.K., Hwang S.N., Snyder P.J. Digital topological analysis of in vivo magnetic resonance microimages of trabecular bone reveals structural implications of osteoporosis. J. Bone Miner. Res. 2001, 16:1520-1531.
10. Wehrli F.W. Structural and functional assessment of trabecular and cortical bone by micro magnetic resonance imaging. J. Magn. Reson. Imaging 2007, 25:390-409.
11. Wehrli F.W., Hwang S.N., Ma J., Song H.K., Ford J.C., Haddad J.G. Cancellous bone volume and structure in the forearm: noninvasive assessment with MR microimaging and image processing. Radiology 1998, 206:347-357.
12. Ladinsky G.A., Vasilic B., Popescu A.M., Wald M., Zemel B.S., Snyder P.J., et al. Trabecular structure quantified with the MRI-based virtual bone biopsy in postmenopausal women contributes to vertebral deformity burden independent of areal vertebral BMD. J. Bone Miner. Res. 2008, 23:64-74.
13. Wehrli F.W., Ladinsky G.A., Jones C., Benito M., Magland J., Vasilic B., et al. In vivo magnetic resonance detects rapid remodeling changes in the topology of the trabecular bone network after menopause and the protective effect of estradiol. J. Bone Miner. Res. 2008, 23:730-740.
14. Heaney R.P., Yates A.J., Santora I.I.A.C. Bisphosphonate effects and the bone remodeling transient. J. Bone Miner. Res. 1997, 12:1143-1151.
15. Greenspan S.L., Holland S., Maitland-Ramsey L., Poku M., Freeman A., Yuan W., et al. Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy. Proc. Assoc. Am. Phys. 1996, 108:230-238.
16. Bone H.G., Hosking D., Devogelaer J.P., Tucci J.R., Emkey R.D., Tonino R.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 2004, 350:11-99.
17. Bonnick S., Saag K.G., Kiel D.P., McClung M., Hochberg M., Burnett S.A.M., et al. de Papp AEftFACTFi. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J. Clin. Endocrinol. Metab. 2006, 91:2631-2637.
18. Visekruna M., Wilson D., McKiernan F.E. Severely suppressed bone turnover and atypical skeletal fragility. J. Clin. Endocrinol. Metab. 2008, 93:2948-2952.
19. Goh S.K., Yang K.Y., Koh J.S.B., Wong M.K., Chua S.Y., Chua D.T.C., et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy. J. Bone Joint. Surg. Br. 2007, 89(3):349-353.
20. Ing-Lorenzini K., Desmeules J., Plachta O., Suva D., Dayer P., Peter R. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Safety 2009, 32(9):775-785.
21. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996, 348:1535-1541.
22. Benito M., Vasilic B., Wehrli F.W., Bunker B., Wald M., Gomberg B., et al. Effect of testosterone replacement on trabecular architecture in hypogonadal men. J. Bone Miner. Res. 2005, 20:1785-1795.
23. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., et al. For the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999, 282:1344-1352.